AR046076A1 - PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION - Google Patents

PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION

Info

Publication number
AR046076A1
AR046076A1 ARP040102543A ARP040102543A AR046076A1 AR 046076 A1 AR046076 A1 AR 046076A1 AR P040102543 A ARP040102543 A AR P040102543A AR P040102543 A ARP040102543 A AR P040102543A AR 046076 A1 AR046076 A1 AR 046076A1
Authority
AR
Argentina
Prior art keywords
precursor cells
population
oligodendrocyte precursor
obtaining
procedures
Prior art date
Application number
ARP040102543A
Other languages
Spanish (es)
Inventor
Hiroshi Okazaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR046076A1 publication Critical patent/AR046076A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)

Abstract

Población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos con estado de desarrollo sincronizado y procedimientos para obtener una población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos. Otros procedimientos incluyen procedimientos para mantener y almacenar una población homogénea de células precursoras de oligodendrocitos durante períodos prolongados sin cambio en las características de las células y procedimientos para diferenciar células precursoras de oligodendrocitos. La población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos o población homogénea de oligodendrocitos pueden ser útil para tratar a un paciente que tiene un desorden o condición del sistema nervioso central. Reivindicación 1: Procedimiento para obtener una población homogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo sincronizado, caracterizado porque comprende cultivar una población heterogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo no sincronizado, en un medio que comprende una cantidad de factor de crecimiento de fibroblasto (FGF) eficaz para inducir una etapa sincronizada de desarrollo y en donde dicho cultivo se lleva a cabo en ausencia sustancial de factor de crecimiento derivado de plaquetas (FCDP), obteniendo así dicha población homogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo sincronizado.Phenotypically homogenous self-renewing population of oligodendrocyte precursor cells with synchronized development status and procedures to obtain a phenotypically homogeneous autorenovating population of oligodendrocyte precursor cells. Other procedures include procedures for maintaining and storing a homogeneous population of oligodendrocyte precursor cells for prolonged periods without change in cell characteristics and procedures for differentiating oligodendrocyte precursor cells. The phenotypically homogenous self-renewing population of oligodendrocyte precursor cells or homogeneous population of oligodendrocytes may be useful for treating a patient who has a disorder or condition of the central nervous system. Claim 1: Method for obtaining a homogeneous population of oligodendrocyte precursor cells that have a synchronized development state, characterized in that it comprises culturing a heterogeneous population of oligodendrocyte precursor cells that have a non-synchronized development state, in a medium comprising an amount of fibroblast growth factor (FGF) effective to induce a synchronized stage of development and wherein said culture is carried out in substantial absence of platelet-derived growth factor (FCDP), thereby obtaining said homogeneous population of oligodendrocyte precursor cells They have a synchronized development status.

ARP040102543A 2003-07-18 2004-07-16 PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION AR046076A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48793303P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
AR046076A1 true AR046076A1 (en) 2005-11-23

Family

ID=34079394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102543A AR046076A1 (en) 2003-07-18 2004-07-16 PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION

Country Status (13)

Country Link
US (1) US20060172415A1 (en)
EP (1) EP1646711A4 (en)
JP (1) JP2007530001A (en)
KR (1) KR20060037346A (en)
CN (1) CN1833021A (en)
AR (1) AR046076A1 (en)
AU (1) AU2004257000B2 (en)
BR (1) BRPI0412715A (en)
CA (1) CA2532216A1 (en)
MX (1) MXPA05014161A (en)
SG (1) SG144166A1 (en)
TW (1) TW200510537A (en)
WO (1) WO2005007797A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597611A1 (en) * 2005-02-11 2006-08-17 Elan Pharmaceuticals, Inc. Methods of identifying genes which modulate myelination
DK1904113T3 (en) * 2005-06-23 2016-03-21 Tissuegene Inc NEURO PROTECTIVE EFFECTIVE CONNECTION
ES2323913B1 (en) * 2006-03-17 2010-05-14 Universidad De Salamanca (Titular Al 65%) SONIC HEDGEHOG MITOGENOUS EFFECT (SHH) ON OLIGODENDROCIT PRECURSORS AND ITS USE IN DEMIELINIZING DISEASES.
JP5703028B2 (en) 2008-01-30 2015-04-15 アステリアス バイオセラピューティクス インコーポレイテッド Synthetic surface for culturing stem cell-derived oligodendrocyte progenitor cells
CA2712891A1 (en) 2008-01-30 2009-08-06 Corning Incorporated Synthetic surfaces for culturing stem cell derived cardiomyocytes
EP2247716B1 (en) * 2008-01-30 2012-04-25 Geron Corporation Synthetic surfaces for culturing cells in chemically defined media
EP2355826A1 (en) * 2008-11-07 2011-08-17 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
US10351823B2 (en) * 2009-11-12 2019-07-16 Q Therapeutics, Inc. Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
CN101735983B (en) * 2009-12-29 2011-07-27 中国人民解放军第三军医大学 Method for separating and purifying oligodendrocyte precursor cells
ES2375860B8 (en) * 2010-03-31 2013-06-10 Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin) METHOD FOR OBTAINING OLIGODENDROCIT PRECURSOR CELLS.
WO2013021381A1 (en) * 2011-08-07 2013-02-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
KR101409336B1 (en) 2012-02-15 2014-06-27 중앙대학교 산학협력단 Composition for Treating Central Nervous System Disease Comprising Oligodendrocyte Progenitor As Active Ingredient
WO2013144999A1 (en) * 2012-03-27 2013-10-03 Okinawa Institute of Science and Technology Graduate University Neuronal culture medium and method for producing in vivo-like and enhanced synaptogenesis neuron model
JP6363096B2 (en) * 2012-12-19 2018-07-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Micropillar array for assaying myelin formation
CN103388007B (en) * 2013-07-25 2016-08-24 宗兆文 A kind of method that mescenchymal stem cell utilizing corium to originate prepares tissue engineering spinal cord
JP6844953B2 (en) * 2015-04-22 2021-03-17 公益財団法人東京都医学総合研究所 Glial cell system targeting Alzheimer's disease research
CN105062956B (en) * 2015-08-21 2018-02-09 北京市虹天济神经科学研究院 People's olfactory mucosa Olfactory essheathing cell is separated, passed on, freezing, differentiation technique
CN105695409B (en) * 2016-03-22 2019-09-27 中国人民解放军第二军医大学 A kind of naked mole oligodendrocyte precursor cells cultural method
WO2017173064A1 (en) 2016-03-30 2017-10-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
US20190262405A1 (en) * 2016-09-14 2019-08-29 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
CN109722418B (en) * 2017-10-29 2023-01-03 复旦大学 Method for obtaining and purifying oligodendrocyte precursor cells of newborn mice
CN108624560B (en) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 Differentiation culture medium and preparation method of oligodendrocyte precursor cells
CN113481161A (en) * 2021-07-30 2021-10-08 四川省医学科学院·四川省人民医院 Culture medium, and induction culture method and application of oligodendrocyte progenitor cells
CN115340982A (en) * 2022-08-23 2022-11-15 徐州医科大学 Method for separating and purifying oligodendrocyte precursor cells in cortical region of newborn mouse

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6361996B1 (en) * 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Also Published As

Publication number Publication date
EP1646711A2 (en) 2006-04-19
MXPA05014161A (en) 2006-05-25
JP2007530001A (en) 2007-11-01
CA2532216A1 (en) 2005-01-27
WO2005007797A3 (en) 2006-05-11
EP1646711A4 (en) 2008-03-19
WO2005007797A2 (en) 2005-01-27
BRPI0412715A (en) 2006-09-26
US20060172415A1 (en) 2006-08-03
SG144166A1 (en) 2008-07-29
KR20060037346A (en) 2006-05-03
AU2004257000B2 (en) 2011-07-21
CN1833021A (en) 2006-09-13
AU2004257000A1 (en) 2005-01-27
TW200510537A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
AR046076A1 (en) PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION
Kuehnle et al. The therapeutic potential of stem cells from adults
Liu et al. Brain injury does not alter the intrinsic differentiation potential of adult neuroblasts
CN103396993B (en) The oligodendroglia of myelinization again and the treatment for spinal cord injury of derived from primate embryonic stem cells
DE60045034D1 (en) OVERHEADS OF MESENCHYM STAMMING CELLS FOR PREVENTING AND TREATING IMMUNE RESPONSES IN TRANSPLANTATIONS
WO2007030469A3 (en) Transplantable cell growth niche and related compositions and methods
ATE514772T1 (en) MULTIPOTENT ADULT STEM CELLS AND METHOD FOR ISOLATION THEREOF
BR0210599A (en) Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
DK1651758T3 (en) Process for Preparation of L-Lysine or L-Threonine Using Escherichia Bacteria with Impaired Malic Enzyme Activity
BRPI0517514A8 (en) IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS
ECSP034548A (en) DERIVATIVES OF QUINOLINONA AS INHIBITORS OF TIROSIN QUINASA
ATE238783T1 (en) MICROBE RESISTANT AND STABILIZED SOLUTIONS CONTAINING GAMMA-HYDROXYBUTRY ACID SALTS FOR THE TREATMENT OF NARCOLEPSY
ATE491026T1 (en) PLY-GBS-LYSINE MUTANTS
ES2167461T3 (en) IN VITRO MODELS OF FUNCTION AND DYSFUNCTION OF THE CENTRAL NERVOUS SYSTEM.
FR2812004B1 (en) CULTURE MEDIA FOR IN VITRO FERTILIZATION, OR FOR THE CULTURE OF FOLLICLES, MALE GERMINAL CELLS OR EMBRYOS
Oliver Adult renal stem cells and renal repair
Peter et al. The role of stem cell strategies in coping with environmental stress and choosing between alternative reproductive modes: Turbellaria rely on a single cell type to maintain individual life and propagate species
AU757036B2 (en) Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies
DK1292672T3 (en) Immobilization carrier comprising a porous medium
WO2003029432A3 (en) Human mesenchymal progenitor cell
AU2002250934A1 (en) Bioartificial primarily vascularized tissue matrix, bioartificial primarily vascularized tissue, method for the production thereof and use of the same
ATE353642T1 (en) USE OF HYPOESTOXIDES AS ANTIPARASITIVE AGENTS
WO2005054447A3 (en) Müller stem cells
DE60132466D1 (en) METHOD FOR CULTURING HUMAN LUNG MAST CELLS AND ITS APPLICATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure